Axsome Therapeutics Q4 EPS $(0.56) Beats $(0.68) Estimate, Sales $195.999M Beat $193.107M Estimate

Axsome Therapeutics, Inc. +3.28%

Axsome Therapeutics, Inc.

AXSM

184.18

+3.28%

Axsome Therapeutics (NASDAQ: AXSM) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.68) by 17.4 percent. This is a 30 percent increase over losses of $(0.80) per share from the same period last year. The company reported quarterly sales of $195.999 million which beat the analyst consensus estimate of $193.107 million by 1.50 percent. This is a 65.03 percent increase over sales of $118.766 million the same period last year.